Triple

T16547992
Position Surface form Disambiguated ID Type / Status
Subject Llansamlet E401994 entity
Predicate contains P35 FINISHED
Object Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
 E1220416 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Talycopa | Statement: [Llansamlet, contains, Talycopa]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Talycopa
Context triple: [Llansamlet, contains, Talycopa]
  • A. Zaltrap
    Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
  • B. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • C. Iclusig
    Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
  • D. Alecensa
    Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
  • E. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Talycopa
Triple: [Llansamlet, contains, Talycopa]
Generated description
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Talycopa
Target entity description: Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
  • A. Zaltrap
    Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
  • B. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • C. Iclusig
    Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
  • D. Alecensa
    Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
  • E. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d88384bc30819084229e7dcdc39a41 completed April 10, 2026, 4:58 a.m.
NER Named-entity recognition batch_69e34fbf79048190b761008441762374 completed April 18, 2026, 9:32 a.m.
NED1 Entity disambiguation (via context triple) batch_6a0067b4f6448190812632ab9023b665 completed May 10, 2026, 11:10 a.m.
NEDg Description generation batch_6a00686f87408190b7d8a41cd54735d8 completed May 10, 2026, 11:13 a.m.
NED2 Entity disambiguation (via description) batch_6a006b6edd7081908730363b267253dd completed May 10, 2026, 11:26 a.m.
Created at: April 10, 2026, 5:15 a.m.